Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KRYS NASDAQ:LNTH NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRYSKrystal Biotech$149.01+3.7%$146.81$122.80▼$207.84$4.30B0.66325,625 shs13,101 shsLNTHLantheus$52.68-0.5%$63.98$47.25▼$118.21$3.58B0.151.20 million shs34,026 shsSRPTSarepta Therapeutics$17.52+0.8%$17.75$10.41▼$138.81$1.73B0.496.31 million shs633,760 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRYSKrystal Biotech0.00%-4.39%-4.39%+8.00%-28.72%LNTHLantheus0.00%-3.31%-2.29%-31.97%-49.84%SRPTSarepta Therapeutics0.00%-7.06%-20.27%-16.95%-86.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRYSKrystal Biotech$149.01+3.7%$146.81$122.80▼$207.84$4.30B0.66325,625 shs13,101 shsLNTHLantheus$52.68-0.5%$63.98$47.25▼$118.21$3.58B0.151.20 million shs34,026 shsSRPTSarepta Therapeutics$17.52+0.8%$17.75$10.41▼$138.81$1.73B0.496.31 million shs633,760 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRYSKrystal Biotech0.00%-4.39%-4.39%+8.00%-28.72%LNTHLantheus0.00%-3.31%-2.29%-31.97%-49.84%SRPTSarepta Therapeutics0.00%-7.06%-20.27%-16.95%-86.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKRYSKrystal Biotech 2.86Moderate Buy$209.0040.26% UpsideLNTHLantheus 2.67Moderate Buy$91.6073.88% UpsideSRPTSarepta Therapeutics 2.07Hold$39.32124.39% UpsideCurrent Analyst Ratings BreakdownLatest SRPT, KRYS, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025SRPTSarepta TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.009/9/2025SRPTSarepta TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$12.00 ➝ $15.008/25/2025SRPTSarepta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell8/22/2025KRYSKrystal BiotechChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$219.00 ➝ $216.008/22/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$240.008/20/2025SRPTSarepta TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderperform$17.008/15/2025SRPTSarepta TherapeuticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$12.008/11/2025LNTHLantheusTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy ➝ Hold$111.00 ➝ $63.008/7/2025LNTHLantheusJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$112.00 ➝ $73.008/7/2025LNTHLantheusMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$120.00 ➝ $70.008/7/2025SRPTSarepta TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$19.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKRYSKrystal Biotech$290.52M14.84$4.81 per share30.98$32.90 per share4.53LNTHLantheus$1.53B2.34$7.06 per share7.46$15.65 per share3.37SRPTSarepta Therapeutics$2.48B0.69$2.45 per share7.14$15.99 per share1.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKRYSKrystal Biotech$89.16M$4.9230.1814.78N/A40.85%15.21%13.81%11/3/2025 (Estimated)LNTHLantheus$312.44M$3.7614.028.35N/A17.82%34.06%19.10%11/5/2025 (Estimated)SRPTSarepta Therapeutics$235.24M-$0.87N/A1.60N/A-2.34%-1.03%-0.37%11/5/2025 (Estimated)Latest SRPT, KRYS, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025LNTHLantheus$1.65$1.57-$0.08$1.12$389.69 million$378.05 million8/6/2025Q2 2025SRPTSarepta Therapeutics$0.89$2.02+$1.13$1.89$530.66 million$611.09 million8/4/2025Q2 2025KRYSKrystal Biotech$1.08$1.29+$0.21$1.29$95.42 million$96.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKRYSKrystal BiotechN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKRYSKrystal BiotechN/A9.689.33LNTHLantheus0.494.294.07SRPTSarepta Therapeutics0.842.891.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKRYSKrystal Biotech86.29%LNTHLantheus99.06%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipKRYSKrystal Biotech13.70%LNTHLantheus2.00%SRPTSarepta Therapeutics7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKRYSKrystal Biotech21028.94 million24.98 millionOptionableLNTHLantheus70067.99 million66.63 millionOptionableSRPTSarepta Therapeutics1,37297.71 million90.29 millionOptionableSRPT, KRYS, and LNTH HeadlinesRecent News About These CompaniesInspire Investing LLC Buys New Holdings in Sarepta Therapeutics, Inc. $SRPT5 hours ago | marketbeat.comQ3 EPS Forecast for Sarepta Therapeutics Raised by AnalystSeptember 13 at 7:21 AM | marketbeat.comLeerink Partnrs Issues Optimistic Forecast for SRPT EarningsSeptember 12 at 8:43 AM | marketbeat.comLeerink Partnrs Issues Positive Outlook for SRPT EarningsSeptember 12 at 2:39 AM | americanbankingnews.comLeerink Partnrs Analysts Boost Earnings Estimates for SRPTSeptember 12 at 2:03 AM | americanbankingnews.comLeerink Partners Raises Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $15.00September 11, 2025 | marketbeat.comBrokerages Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Price Target at $43.50September 11, 2025 | americanbankingnews.com15,163 Shares in Sarepta Therapeutics, Inc. $SRPT Bought by Scientech Research LLCSeptember 10, 2025 | marketbeat.comLeerink Partners Issues Positive Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock PriceSeptember 10, 2025 | americanbankingnews.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Rating of "Hold" by AnalystsSeptember 9, 2025 | marketbeat.comEventide Asset Management LLC Lowers Position in Sarepta Therapeutics, Inc. $SRPTSeptember 6, 2025 | marketbeat.comSarepta Therapeutics, Inc. $SRPT Stock Holdings Lifted by EcoR1 Capital LLCSeptember 6, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Shares Up 6.1% - Still a Buy?September 5, 2025 | marketbeat.comSarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic YearSeptember 5, 2025 | businesswire.comSarepta Therapeutics, Inc. $SRPT Shares Purchased by 683 Capital Management LLCSeptember 4, 2025 | marketbeat.comADAR1 Capital Management LLC Acquires 82,919 Shares of Sarepta Therapeutics, Inc. $SRPTSeptember 4, 2025 | marketbeat.comSarepta Therapeutics, Inc. $SRPT Shares Sold by Vestal Point Capital LPSeptember 4, 2025 | marketbeat.comPDT Partners LLC Raises Stock Holdings in Sarepta Therapeutics, Inc. $SRPTSeptember 4, 2025 | marketbeat.comSarepta Therapeutics (SRPT) Fell Despite Reporting Good ResultsSeptember 3, 2025 | finance.yahoo.comSarepta Therapeutics, Inc. $SRPT Shares Sold by Braidwell LPSeptember 3, 2025 | marketbeat.comSarepta Therapeutics Restructures Amid ELEVIDYS ChallengesSeptember 1, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSRPT, KRYS, and LNTH Company DescriptionsKrystal Biotech NASDAQ:KRYS$149.01 +5.33 (+3.71%) As of 10:06 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Lantheus NASDAQ:LNTH$52.68 -0.26 (-0.49%) As of 10:06 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Sarepta Therapeutics NASDAQ:SRPT$17.52 +0.13 (+0.76%) As of 10:06 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
